In the present study, we investigated the distribution of CD133, Olig2 and CD44 expressing patient-derived GBM cells in vitro and in vivo to determine the stability of these cell subpopulations in response to environmental perturbations/challenges. The gene discussed is CD44; the disease is glioblastoma.